Pharmacology and toxicology of cannabis derivatives and endocannabinoid agonists

Recent Patents on CNS Drug Discovery

Volumn 5, Issue 1, 2010, Pages 46-52

  Gerra, Gilberto ^a   Zaimovic, Amir ^b   Gerra, Maria L ^c   Ciccocioppo, Roberto ^d   Cippitelli, Andrea ^d   Serpelloni, Giovanni ^e   Somaini, Lorenzo ^f  

^a United Nations Office on Drugs and Crime Austria   (Austria)

^b Programma Dipendenze SerT   (Italy)

^c UNIVERSITY OF PARMA   (Italy)

^d UNIVERSITY OF CAMERINO   (Italy)

^e Dipartimento Dipendenze ASL Verona   (Italy)

^f ASL BI   (Italy)

Author keywords

Abuse; Cannabis; Endocannabinoids; Receptor agonists

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 [4 (1,1 DIMETHYLHEPTYL) 2,6 DIMETHOXYPHENYL] 6,6 DIMETHYLBICYCLO[3.1.1]HEPT 2 EN 2 YLMETHANOL; ANANDAMIDE; CANNABIDIOL; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABIS; DEXANABINOL; DRONABINOL; ENDOCANNABINOID AGONIST; ICOSANOID; NABILONE; UNCLASSIFIED DRUG; CANNABINOID; CANNABINOID 1 RECEPTOR; ENDOCANNABINOID;

CACHEXIA; CENTRAL NERVOUS SYSTEM; CHRONIC PAIN; CLINICAL FEATURE; COGNITION; COMORBIDITY; DRUG DEPENDENCE; GLAUCOMA; HUMAN; LEARNING; LOCOMOTION; MEMORY; MENTAL DISEASE; MULTIPLE SCLEROSIS; NAUSEA; NONHUMAN; PATENT; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; VOMITING; ANIMAL; CANNABIS ADDICTION; CENTRAL NERVOUS SYSTEM DISEASE; DRUG EFFECT; DRUG POTENTIATION; METABOLISM; PATHOPHYSIOLOGY; PHYTOTHERAPY;

ANIMALS; CANNABINOIDS; CANNABIS; CENTRAL NERVOUS SYSTEM DISEASES; ENDOCANNABINOIDS; HUMANS; LEARNING; MARIJUANA ABUSE; PATENTS AS TOPIC; PHYTOTHERAPY; RECEPTOR, CANNABINOID, CB1;

EID: 77449148434     PISSN: 15748898     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488910789753521     Document Type: Review

References (114)

1. Devane WA, Dysarz FA, Johnson M, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharm 1988; 34(5): 605-613.
2. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346(6284): 561-564.
3. Devane WA, Hanus L, Breuer A. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258: 1946-1949.
4. Mechoulam R, Ben-Shabat S, Hanus L, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995; 50(1): 83-90
5. Sugiura T, Kondo S, Sukagawa A, et al. 2-Arachidonoylglycerol: A possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995; 215(1): 89-97.
6. Piomelli D. The molecular logic of endocannabinoid signalling. Nature Rev Neurosci 2003; 4(11): 873-884.
7. Rodriguez de fonseca F, Del Arco I, Bermudez-Silva FJ, Bilbao A, Cippitelli A, Navarro M. The endocannabinoid system: Physiology and pharmacology. Alcohol Alcohol 2005; 40 (1): 2-14.
8. Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006; 58(3): 389-462.
9. Pacher P, Mukhopadhyay P, Mahonraj R, Godlewski G, Batkai S, Kunos G. Modulation of the endocannabinoid system in cardiovascular disease: Therapeutic potential and limitations. Hypertension 2008; 52(4): 601-607.
10. Kunos G, Osei-Hyiaman D, Batkai S, Sharkey KA, Makriyannis A. Should peripheral CB(1) cannabinoidi receptors be selectively targeted for therapeutic gain? Trends Pharmacol Sci 2009; 30(1):1-7.
11. Kunos G, Osei-Hyiaman D, Liu J, Godlewski G, Batkai S. Endocannabinoids and the control of energy homeostasis. J Biol Chem 2008; 283(48): 33021-33025.
12. Howlett AC, Barth F, Bonner TI, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002; 54(2): 161-202.
13. Janero DR, Makriyannis A. Targeted modulators of the endogenous cannabinoid system: Future medications to treat addiction disorders and obesity. Curr Psychiatry Rep 2007; 9(5): 365-373
14. Pertwee RG. The central pharmacology of psychotropic Cannabinoids. Pharmacol Ther 1998; 36: 189-261.
15. House of Lords, The United Kingdom Parliament 1998. http://www. parliament.the-stationeryoffice.co.uk/pa/ld199798/ldselect/ldsctech/151/15101. htm
16. Wade DT, Robson P, House H, Makela P, Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 2003; 17: 21-29.
17. Berman JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: Results of a randomised controlled trial. Pain 2004; 112(3): 299-306.
18. Pryce G, Baker D. Emerging properties of cannabinoid medicines in management of multiple sclerosis. Trends Neurosci 2005; 28(5): 272-276.
19. Kalant H. Adverse effects of cannabis on health: An update of the literature since 1996. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28(5): 849-863
20. Gonzalez R. Acute and non-acute effects of cannabis on brain functioning and neuropsychological performance. Neuropsychol Rev 2007; 17(3): 347-361.
21. Vadhan NP, Hart CL, Van Gorp WG, et al. Acute effects of smoked marijuana on decision making, as assessed by a modified gambling task, in experienced marijuana users. J Clin Exp Neuropsychol 2007; 29(4): 357-364.
22. Lundqvist T. Cognitive consequences of cannabis use: Comparison with abuse of stimulants and heroin with regard to attention, memory and executive functions. Pharmacol Biochem Behav 2005; 81(2): 319-330.
23. Almeida PP, Novaes MA, Bressan RA, Lacerda AL. Review: Executive functioning and Cannabis use. Rev Bras Psiquiatr 2008; 30(1): 69-76.
24. McHale S, Hunt N. Executive function deficits in short-term abstinent Cannabis users. Hum Psychopharmacol 2008; 23(5): 409-415.
25. Harrison GP Jr, Gruber AJ, Hudson JI, Huestis MA, Yurgelun-Todd D. Cognitive measures in long-term Cannabis users. J Clin Pharmacol 2002; 42(11 Suppl): 41S-47S.
26. Núñez-Domínguez LA. Cognitive deterioration after consumption of Cannabis. Rev Neurol 2001; 33(5): 482-486.
27. Riedel G, davies SN. Cannabionid function in learning, memory and plasticity. Handb Exp Pharmacol 2005; 168: 445-477.
28. Ademark L, Talani G, Lovinger DM. Endocannabinoid-dependent plasticity at GABAergic and glutammatergic synapse in the striatum is regulated by synaptic activity. Eur J Neurosci 2009; 29(1): 32-41.
29. Nestor L, Roberts G, Garavan H, Hester R. Deficits in learning and memory: Parahippocampal hyperactivity and frontocortical hypoactivity in cannabis users. Neuroimage 2008; 40(3):1328-1339.
30. Eldreth DA, Matochik JA, Cadet JL, Bolla KI. Abnormal brain activity in prefrontal brain regions in abstinent marijuana users. Neuroimage 2004; 23(3): 914-920.
31. Takahashi RN, Pamplona Fa, Fernandes MS. The cannabinoid antagonist SR141716A facilitates memory acquisition and consolidation in the house elevated T-maze. Neurosci Lett 2005; 380(3): 270-275.
32. Riedel G, Davies SN. Cannabinoid function in learning, memory and plasticity. Handb Exp Pharmacol 2005; 168: 445-477.
33. Macie K. Distribution of cannabinoidi receptors in the central and peripheral nervous system. Handb Exp Pharmacol 2005; 168; 299-325.
34. Weisntein A, Brickner O, Lerman H, et al. Brain imaging study of the acute effects of Delta9-tetrahydrocannabinoil (THC) on attention and motor coordination in regular users of marijuana. Psychopharmacology (Berl) 2008; 196(1): 119-131.
35. Rodrigez de Fonseca F, Del Arco I, Martin-Calderon JL, Goritti MA, Navarro M. Role of the endogenous cannabinoid system in the regulation of motor activity. Neurobiol Dis 1998; 5(6 PT B): 483-501.
36. Roser P. Gallinat J, Weinberg G, Juckel G, Gorynia I, Stadelmann AM. Psychomotor performance in relation to acute oral administration of Delta9-tetrahydrocannabinol and standardized cannabis extract in healthy human subjects Eur Arch Psychiatry Clin Neurosci 2009; 259(5): 284-92.17.
37. Sañudo-Peña MC, Romero J, Seale GE, Fernandez-Ruiz JJ, Walker JM. Activational role of cannabinoids on movement. Eur J Pharmacol 2000; 391(3): 269-274.
38. Ramaekers JG, Berghaus G, Van Laar M, Drummer OH. Dose related risk of motor vehicle crashes after Cannabis use. Drug Alcohol Depend 2004; 73(2): 109-119.
39. Khiabani HZ, Christophersen AS, Mørland J. Cannabis affects driving skills. Tidsskr Nor Laegeforen 2007; 127(5): 583-584.
40. Weinstein A, Brickner O, Lerman H, et al. A study investigating the acute dose-response effects of 13mg and 17mg Delta 9-tetrahydrocannabinol on cognitive-motor skills, subjective and autonomic measures in regular users of marijuana. J Psychopharmacol 2008; 22(4):441-451.
41. Hunault CC, Mensinga TT, Böcker KB, et al. Cognitive and psychomotor effects in males after smoking a combination of tobacco and Cannabis containing up to 69 mg delta-9-tetrahydrocannabinol (THC). Psychopharmacology 2008; 201(2): 171-181.
42. Fergusson DM, Boden JM, Horwood LJ. Cannabis use and other illicit drug use: Testing the cannabis gateway hypothesis. Addiction 2006; 101(4): 556-569.
43. Hall WD. Cannabis use and the mental health of young people. Aust N Z J Psychiatry 2006; 40(2):105-113.
44. Lynskey MT, Heath AC, Bucholz KK, et al. Escalation of drug use in early-onset cannabis users vs co-twin controls. JAMA 2003; 289(4): 427-433.
45. Robledo P, Berrendero F, Ozaita A, Maldonado R. Advances in the field of cannabinoid-opioid cross-talk. Addict Biol 2008; 13(2): 213-224.
46. Fattore L, Deiana S, Spano SM, et al. Endocannabinoid system and opioid addiction: Behavioural aspects. Pharmacol Biochem Behav 2005; 81(2): 343-359.
47. Maldonado R, Valverde O, Berrendero F. Involvement of the endocannabinoid system in drug addiction. Trends Neurosci 2006; 29(4): 225-232.
48. Economidou D, Mattioli L, Cifani C, et al. Effect of the cannabinoid CB1 receptor antagonist SR-1411716° on ethanol self-administration and ethanol-seeking behaviour in rats. Psychopharmacology 2006; 183(4): 394-403.
49. Moreira FA, Lutz B. The endocannabinoid system: Emotion, learning and addiction. Addict Biol 2008; 13(2): 196-212.
50. Bovasso GB. Cannabis abuse as a risk factor for depressive symptoms. Am J Psychiatry 2001; 158(12): 2033-2037.
51. Tournier M, Sorbara F, Gindre C, Swendsen JD, Verdoux H. Cannabis use and anxiety in daily life: A naturalistic investigation in a non-clinical population. Psychiatry Res 2003; 118(1): 1-8.
52. Pedersen W. Does cannabis use lead to depression and suicidal behaviours? A population-based longitudinal study. Acta Psychiatr Scand 2008; 118(5): 395-403.
53. Watzke AB, Schmidt CO, Zimmermann J, Preuss UW. Personality disorders in a clinical sample of Cannabis dependent young adults. Fortschr Neurol Psychiatr 2008; 76(10): 600-605.
54. Frisher M, Crome I. Martino O, Croft P. assessing the impact of cannabis use on trends in diagnosed schizophrenia in the United Kingdom from 1996 to 2005. Schizophr Res 2009; 113(2-3): 123-128.
55. Schofield D, Tennat C, Nash L, et al. Reasons for Cannabis use in psychosis. Austr N Z L Psychiatry 2006; 40(6-7): 570-574.
56. Kawohl W, Rössler W. Cannabis and Schizophrenia: New findings in an old debate. Neuropsychiatry 2008; 22(4): 223-229.
57. Luzi S, Morrison PD, Powell J, di Forti M, Murray RM. What is the mechanism whereby cannabis use increases risk of psychosis? Neurotox Res 2008; 14(2-3): 105-112.
58. Scott J, Martin G, Bor W, Sawyer M, Clark J, McGrath J. The prevalence and correlates of hallucinations in Australian adolescents: Results from a national survey. Schizophr Res 2009; 107(2-3): 179-185.
59. Guy, G., Platt, B.: GB2434312A (2007).
60. Morgan CJ, Curran HV. Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br J Psychiatry 2008; 192(4): 306-307.
61. Di Forti M, Morrison PD, Butt A, Murray RM. Cannabis use and psychiatric and cognitive disorders: The chicken or the egg? Curr Opin Psychiatry 2007; 20(3): 228-234.
62. Laqueille X, Launay C, Kanit M. Induced psychiatric and somatic disorders to cannabis. Ann Pharm Fr 2008; 66(4): 245-254.
63. Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: A systematic review. Lancet 2007; 370(9584): 319-328.
64. Adams IB, Martin BR. Cannabis: Pharmacology and toxicology in animals and humans. Addiction 1996; 91:1985-11614
65. Burns TL, Ineck JR. Cannabinoid analgesia as a potential new therapeutic option in the treatment of chronic pain. Ann Pharmacother 2006; 40(2): 251-260
66. Rahn EJ, Hohmann AG. Cannabinoids as pharmacotherapies for neuropathic pain: From the bench to the bedside. Neurotherapeutics 2009; 6(4): 713-737.
67. Walsh D, Nelson KA, Mahmoud FA. Established and potential therapeutic applications of cannabinoids in oncology. Supp Care Cancer 2003; 11(3): 137-143.
68. Barbato, L.: WO2007002186 (2007).
69. Coulsom, C.M., Tennant, C.G., Perdices, M.: WO2006017892 (2006).
70. Kikuchi, T., Maeda, K., Guy, G., Robson, P., Stott, C.: WO2009087351 (2009).
71. Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964; 86: 1646-2164
72. Mechoulam. Marihuana chemistry. Science 1970; 168(936): 1159-1166.
73. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC. Characterization and localization of cannabinoid receptors in rat brain: A quantitative in vitro autoradiographic study. J Neurosci 1991; 11(2): 563-583.
74. Howlett AC. The cannabinoidi receptors. Prostaglandins Other Lipid Mediat 2002; 68-69: 619-631.
75. Mauler F, Mittendorf J, Horvath E, De Vry J. Characterization of the diarylether sulfonylester (-)-I-3- (2-hydroxymethylindanyl-4-oxy)phenyl-4,4,4- trifluoro-1-sulfonate ( BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties. J Pharmacol Exp Ther 2002; 302(1): 359-368.
76. Tarzia G, Duranti A, Tontini A, et al. Synthesis and structure-activity relationships of a series of pyrrole cannabinoid receptor agonists. Bioorg Med Chem 2003; 11(18): 3965-3973.
77. Hanus L, Breuer A, Tchilibon S, et al. HU-308: A specific agonist for CB2, a peripheral cannabinoid receptor. Proc Natl Acad Sci USA 1999; 96(25): 14228-14233.
78. Mechulam, R., Kogan, N.: WO2008107878 (2008).
79. Herkenham M, Lynn AB, Little MD, et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 1990; 87: 1932-1936.
80. Pacheco M, Childers SR, Arnold R, Casiano F, Ward SJ. Aminoalkylindoles: Actions on specific G-protein-linked receptors. J Pharmacol Exp Ther 1991; 257(1): 170-183.
81. Srivastava, B., Patel, P.R.: WO2009063495 (2009).
82. Moore, B.M., Bhattacharjee, H., Yates, C.R., Stuart, L.: WO2008109027 (2008).
83. Hillard CJ, Manna S, Greenberg MJ, et al. Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). Pharm Exp Ther 1999; 289(3): 1427-1433.
84. Colombo G, Serra S, Brunetti G, et al. Stimulation of voluntary ethanol intake by cannabinoid receptor agonists in ethanol-preferring sP rats. Psychopharmacology 2002; 159(2): 181-187.
85. Colombo G, Serra S, Vacca G, Gessa GL, Carai MA. Suppression by baclofen of the stimulation of alcohol intake induced by morphine and WIN 55,212-2 in alcohol-preferring rats. Eur J Pharmacol 2004; 492(2-3): 189-193.
86. Gallate JE, Saharov T, Mallet PE, McGregor IS. Increased motivation for beer in rats following administration of a cannabinoid CB1 receptor agonist. Eur J Pharmacol 1999; 370(3): 233-240.
87. McGregor IS, Dam KD, Mallet PE, Gallate JE. Delta9-THC reinstates beer- and sucrose-seeking behaviour in abstinent rats: comparison with midazolam, food deprivation and predator odour. Alcohol Alcohol 2005; 40(1):35-45.
88. Lopez-Moreno JA, Trigo-Diaz JM, Rodriguez de Fonseca F, et al. Nicotine in alcohol deprivation increases alcohol operant sel-administration during reinstatement. Neuropharmacology 2004; 47(7): 1036-1044.
89. Pertwee RG. Emerging startegies for exploiting cannabinoid receptor agonists as medicine. Br J Pharmacol 2009; 156(3): 397-411.
90. Hanus L, Gopher A, Almog S, Mechoulam R. Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J Med Chem 1993; 36(20): 3032-3034.
91. Hanus L, Abu-Lafi S, Fride E, et al. 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci USA 2001; 98(7): 3662-3665.
92. Porter AC, Sauer JM, Knierman MD, et al. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 2002; 301(3): 1020-1024.
93. Bisogno T, Melck D, Bobrov MY, et al. N-acyl-dopamines: Novel synthetic CB1 cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem J 2000; 351(Pt 3): 817-824.
94. Stella N, Schweitzer P, Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature 1997; 388: 773-778.
95. Cadas H, Gaillet S, Beltramo M, Venance L, Piomelli D. Biosynthesis of an endogenous cannabinoid precursor in neurons and its control by calcium and cAMP. J Neurosci 1996; 16(12): 3934-3942.
96. Beltramo M, Stella N, Calignano A, Lin SY, Makriyannis A, Piomelli D. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 1997; 277(5329): 1094-1097.
97. Giuffrida A, Beltramo M, Piomelli D. Mechanisms of endocannabinoid inactivation: Biochemistry and pharmacology. J Pharmacol Exp Ther 2001; 298(1): 7-14.
98. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 1996; 384 (6604): 83-87.
99. Dinh TP, Carpenter D, Leslie FM, et al. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci USA 2002; 99(21): 10819-10824.
100. Gulyas AI, Cravatt BF, Bracey MH, et al. Segregation of two endocannabinoid-hydrolyzing enzymes into pre and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala. Eur J Neurosci 2004; 20(2): 441-458.
101. Kaczocha M, Glaser ST, Deutsch DG. Identification of intracellular carriers for the endocannabionoid anandamide. Proc Natl Acad Sci USA 2009; 106(15): 6375.
102. Makriyannis, A., Pandarinathan, L., Zvonok, N., Parkkari, T., Chapman, L.: WO2009117444 (2009).
103. Makriyannis, A., Nikas, S.P., Alapafuja, S.O., Shukla, V.: WO2009052320 (2009).
104. Cipitelli A, Cannella N, Branconi S, et al. Increase of brain endocannabinoid anandamide levels by FAAH inhibition and alcohol abuse bevaviours in the rat. Psychopharmacology 2008; 198(4): 449-460
105. Solinas M, Panlilio LV, Tanda G, Makriyannis A, Matthews SA, Goldberg SR. Cannabinoidi agonists but not inhibitors of endogenous cannabinoidi transport or metabolism enhance the reinforcing efficacy of heroin in rats. Neuropsychopharmacology 2005; 30(11): 2046-2057.
106. Justinova Z, Manieri Ra, Bortolato M, et al. Fatty acid amide hydrolase heightens anandamide signalling without producing reinforcing effects in primates. Biol Psychiatry 2008; 64(11): 930-937
107. Scherma M, Panlilio LV, Fadda P, et al. Inhibition of anandamide hydrolysis by ciclohexyl carbamic acid 3-cabamoyl-3-yl ester (URB597) reverses abuse-related behavioural and neurochemical effects of nicotine in rats. J Pahramacol Exp Ther 2008; 327(2): 482-490.
108. Forget B Coen KM, le Foll B. Inhibition of fatty acide amide hydrolase reduces reinstatement of nicotine seeking but not break point for nicotine self-administration-comparison with CB(1) receptor blockade. Psychopharmacology 2009; 205(4): 613-624.
109. Cippitelli A, Bilbao A, Navarro M, et al. Selective reduction of ethanol self-administration by the Anandamide trasport inhibitor AM 404. Eur J Neurosci 2005; 21(8): 2243-2251.
110. Vlachov S, Stamatopoulou F, Nomikos GG, Panagis G. enhancement of endocannabinoid neurotransmission through CB1 cannabinoid receptors counteracts the reinforcing and psychostimulant effects of cocaine. Int J Neuropsychopharmacol 2008; 11(7): 905-923.
111. Pacher P, Batkai S, Kunos G. The endocannabiond system as an emerging target of pharmacotherapy. Pharmacol rev 2006; 58(3): 389-462.
112. Clapper JR, Magieri RA, Piomelli D. the endocannabiond system as a target for the treatment of Cannabis dependence. Neuropharmacology 2009; 56(Suppl 1): 235-243.
113. Piomelli D, Tarzia G, Duranti A, et al. Pharmachological profile of the selective FAAH inhibitor KDS-4103 (URB597). CNS Drug Rev 2006; 12(1) 21-38.
114. Akopian AN, Ruparel NB, Jeske NA, Patwardhan A, Hargreaves KM. Role of ionotropic cannabinoid receptors in peripheral antinociception and antihyperalgesia. Trends Pharmacol Sci 2009; 30(2): 79-84.